High ROR1 gene expression in the I-SPY2 transcriptomic dataset was associated with worse event-free survival in hormone receptor (HR)+/HER2− patients with high residual cancer burden after neoadjuvant treatment [12]. The gene discussed is ROR1; the disease is cancer.